These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 31419569)
1. Urgent Time to Allogeneic Hematopoietic Cell Transplantation: A National Survey of Transplant Physicians and Unrelated Donor Search Coordinators Facilitated by the Histocompatibility Advisory Group to the National Marrow Donor Program. Pidala J; Mupfudze TG; Payton T; Barker J; Perales MA; Shaw BE; Fernández-Viña M; Burns LJ; Dehn J Biol Blood Marrow Transplant; 2019 Dec; 25(12):2501-2506. PubMed ID: 31419569 [TBL] [Abstract][Full Text] [Related]
2. Outcomes of Related and Unrelated Donor Searches Among Patients with Primary Immunodeficiency Diseases Referred for Allogeneic Hematopoietic Cell Transplantation. Acevedo MJ; Wilder JS; Adams S; Davis J; Kelly C; Hilligoss D; Carroll E; Blacklock-Schuver B; Cole K; Kang EM; Hsu AP; Kanakry CG; Dimitrova D; Kanakry JA Biol Blood Marrow Transplant; 2019 Aug; 25(8):1666-1673. PubMed ID: 30986499 [TBL] [Abstract][Full Text] [Related]
3. Meeting the Demand for Unrelated Donors in the Midst of the COVID-19 Pandemic: Rapid Adaptations by the National Marrow Donor Program and Its Network Partners Ensured a Safe Supply of Donor Products. Auletta JJ; Novakovich JL; Stritesky GL; Newman J; Fridy-Chesser ST; Hailperin K; Devine SM Transplant Cell Ther; 2021 Feb; 27(2):133-141. PubMed ID: 33830022 [TBL] [Abstract][Full Text] [Related]
5. Likelihood of Proceeding to Allogeneic Hematopoietic Cell Transplantation in the United States after Search Activation in the National Registry: Impact of Patient Age, Disease, and Search Prognosis. Dehn J; Chitphakdithai P; Shaw BE; McDonald AA; Devine SM; Burns LJ; Spellman S Transplant Cell Ther; 2021 Feb; 27(2):184.e1-184.e13. PubMed ID: 33045385 [TBL] [Abstract][Full Text] [Related]
6. Donation activities and product integrity in unrelated donor allogeneic hematopoietic transplantation: experience of the National Marrow Donor Program. Bolan CD; Hartzman RJ; Perry EH; Trainor L; Miller J; Miller R; Hanley L; Chitphakdithai P; King RJ Biol Blood Marrow Transplant; 2008 Sep; 14(9 Suppl):23-8. PubMed ID: 18721777 [TBL] [Abstract][Full Text] [Related]
7. Unrelated donor stem cell transplantation: the role of the National Marrow Donor Program. Karanes C; Confer D; Walker T; Askren A; Keller C Oncology (Williston Park); 2003 Aug; 17(8):1036-8, 1043-4, 1164-7. PubMed ID: 12966671 [TBL] [Abstract][Full Text] [Related]
8. The National Marrow Donor Program: improving access to hematopoietic cell transplantation. Walker T; Milford E; Chell J; Maiers M; Confer D Clin Transpl; 2011; ():55-62. PubMed ID: 22755401 [TBL] [Abstract][Full Text] [Related]
9. Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP/CIBMTR. Dehn J; Spellman S; Hurley CK; Shaw BE; Barker JN; Burns LJ; Confer DL; Eapen M; Fernandez-Vina M; Hartzman R; Maiers M; Marino SR; Mueller C; Perales MA; Rajalingam R; Pidala J Blood; 2019 Sep; 134(12):924-934. PubMed ID: 31292117 [TBL] [Abstract][Full Text] [Related]
10. Expanding donor options: haploidentical transplant recipients are also highly likely to have a 7/8-matched unrelated donor. Fingerson S; Maiers M; Bolon YT; Devine SM; Spellman SR Blood Adv; 2024 Feb; 8(3):758-765. PubMed ID: 38127270 [TBL] [Abstract][Full Text] [Related]
11. Challenges and potential solutions for recruitment and retention of hematopoietic cell transplantation physicians: the National Marrow Donor Program's System Capacity Initiative Physician Workforce Group report. Burns LJ; Gajewski JL; Majhail NS; Navarro W; Perales MA; Shereck E; Selby GB; Snyder EL; Woolfrey AE; Litzow MR Biol Blood Marrow Transplant; 2014 May; 20(5):617-21. PubMed ID: 24508838 [TBL] [Abstract][Full Text] [Related]
12. The national marrow donor program 20 years of unrelated donor hematopoietic cell transplantation. Ballen KK; King RJ; Chitphakdithai P; Bolan CD; Agura E; Hartzman RJ; Kernan NA Biol Blood Marrow Transplant; 2008 Sep; 14(9 Suppl):2-7. PubMed ID: 18721774 [TBL] [Abstract][Full Text] [Related]
13. Unrelated donor choices for allogeneic hematopoietic cell transplantation in Canada: an evaluation of factors influencing donor selection. Greco-Stewart V; Kiernan J; Killeen D; Haun S; Mercer D; Young K; Liwski RS; Allan DS Transfusion; 2018 Mar; 58(3):718-725. PubMed ID: 29277913 [TBL] [Abstract][Full Text] [Related]
14. Chances of Finding Matched Unrelated Donors for Saudi Patients in Need of Hematopoietic Stem Cell Transplantation. Jawdat D; Almutairi Y; Almutairi Z; Almusa A; Hajeer A Transplant Cell Ther; 2021 May; 27(5):423.e1-423.e7. PubMed ID: 33781751 [TBL] [Abstract][Full Text] [Related]
15. Allogeneic transplant physician and center capacity in the United States. Majhail NS; Murphy EA; Omondi NA; Robinett P; Gajewski JL; LeMaistre CF; Confer D; Rizzo JD Biol Blood Marrow Transplant; 2011 Jul; 17(7):956-61. PubMed ID: 21540121 [TBL] [Abstract][Full Text] [Related]
16. The US National Marrow Donor Program role in unrelated donor hematopoietic cell transplantation. Confer D; Robinett P Bone Marrow Transplant; 2008 Aug; 42 Suppl 1():S3-S5. PubMed ID: 18724295 [TBL] [Abstract][Full Text] [Related]